|
The user facility reported a patient with cardiogenic shock from an acute myocardial infarction was implanted with an impella 5.5 device for mechanical circulatory support and experienced a hemorrhagic stroke with a demised outcome.The patient was escalated from a impella cp to the impella 5.5 for hemodynamic support.Six days into support, the patient remained intubated and sedated but followed commands, and the patient was noted to have experienced a subarachnoid bleed.Heparin was put back into purge after repeat head computed tomography scan.Of note, unrelated, it was documented that the patient was being treated for a fungal infection in lungs.Care was eventually withdrawn four days later, and the patient expired.No further information was noted.
|
|
The impella device was not received from the customer, therefore, investigation of the device was not possible.Should the device or any new information be received, a supplemental mdr will be filed.Instructions for use for the related event are as follows: impella 5.5 with smart assist for use during cardiogenic shock section: potential adverse events ¿acute renal dysfunction, aortic valve injury, bleeding, cardiogenic shock, cerebral vascular accident/stroke, death, hemolysis, limb ischemia, myocardial infarction, renal failure, thrombocytopenia and cardiac or vascular injury¿ (including ventricular perforation).
|